Janux Therapeutics (JANX) Long-Term Debt Issuances (2020 - 2021)

Janux Therapeutics' (JANX) quarterly Long-Term Debt Issuances came in at -$69.1 million in Q3 2021, down 1646.97% year-on-year from $4.5 million in Q3 2020, and down 200.4% on a QoQ basis from $68.8 million in Q2 2021.

Janux Therapeutics (JANX) Long-Term Debt Issuances (2020 - 2021) Analysis & Trends

Janux Therapeutics (JANX) has 2 years of Long-Term Debt Issuances data on file, last reported at -$69.1 million in Q3 2021.

  • On a quarterly basis, Long-Term Debt Issuances fell 1646.97% year-over-year to -$69.1 million in Q3 2021; TTM through Jun 2022 was -$69.1 million, a 155.36% decrease from a year earlier, with the FY2021 full-year figure at $55.7 million, changed N/A from the prior year.
  • Long-Term Debt Issuances for Q3 2021 stood at -$69.1 million, down from $68.8 million in the prior quarter.
  • Over the last five years, Long-Term Debt Issuances for JANX reached as high as $68.8 million in Q2 2021 and fell as low as -$69.1 million in Q3 2021.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Janux Therapeutics 985.11 Mn 985.11 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2021 -69.10 Mn
Sep 30, 2021 -69.10 Mn
Jun 30, 2021 68.83 Mn
Jun 30, 2021 68.83 Mn
Mar 31, 2021 56.00 Mn
Mar 31, 2021 56.00 Mn
Dec 31, 2020 -4.47 Mn
Dec 31, 2020 -4.47 Mn
Sep 30, 2020 4.47 Mn
Sep 30, 2020 4.47 Mn